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InﬂammationObesity and its associated complications, which can lead to the development of metabolic syndrome, are a
worldwidemajor public health concern especially indevelopedcountrieswhere they have a veryhigh prevalence.
RIP140 is a nuclear coregulator with a pivotal role in controlling lipid and glucose metabolism. Genetically
manipulatedmicedevoid of RIP140 are leanwith increasedoxygenconsumption and are resistant to high-fat diet-
inducedobesity andhepatic steatosiswith improved insulin sensitivity.Moreover,white adipocyteswith targeted
disruption of RIP140 express genes characteristic of brown fat including CIDEA and UCP1 while skeletal muscles
show a shift in ﬁbre type composition enriched in more oxidative ﬁbres. Thus, RIP140 is a potential therapeutic
target inmetabolic disorders. In this articlewewill review the role of RIP140 in tissues relevant to the appearance
and progression of the metabolic syndrome and discuss how the manipulation of RIP140 levels or activity might
represent a therapeutic approach to combat obesity and associated metabolic disorders. This article is part of a
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Obesity has reached worldwide epidemic proportions, especially
in Western countries, often associated with metabolic dysfunctions
such as insulin resistance, dyslipidaemia, cardiovascular disease and
even some cancers [1–3]. The clustering of these metabolic dysfunc-
tions is recognized as the metabolic syndrome and the component
disorders are essentially caused by a positive energy imbalance,
where nutrient uptake is greater than energy expenditure. Strong
epidemiological links between obesity, type II diabetes and cardio-vascular diseases have suggested a common molecular pathogenesis.
A limit on adipose tissue expandability has been proposed to provide a
unifying causal link to the development of metabolic syndrome [4–6].
Challenging the body with nutrient excess for a prolonged period of
time results in lipid deposition in adipose tissue. Adipose tissue
expands in order to accommodate the excess of energy with
adipocytes undergoing hypertrophy (increase in size) and hyperplasia
(increase in number) to fulﬁl the increased demand for lipid storage.
Hypertrophic adipocytes have an altered proﬁle of adipokine
secretion: a decrease in hormones/cytokines that promote insulin
sensitivity, including adiponectin, and an increase in those that
promote insulin resistance, such as resisitin and retinol binding
protein (RBP) 4, and inﬂammation, such as interleukin (IL) 6 and
tumour necrosis factor (TNF) α [7–9]. These inﬂammatory molecules
recruit and activate macrophages present in the tissue to trigger low-
grade inﬂammation in adipose tissue. Furthermore, activated macro-
phages block preadipocyte recruitment and limit hyperplasic expan-
sion of the adipose tissue. Once the storage capacity of the adipose
tissue is exceeded, lipids start to accumulate in non-adipose tissues,
leading to lipotoxicity [10,11]. Steatosis of the liver, muscle, pancreas,
heart, and kidney can lead to organ failure or exacerbate whole-body
insulin resistance. In addition, increased levels of circulating free fatty
acids (FAs) and development of type II diabetes are major risk factors
for development of atherosclerosis and cardiovascular complications
[12].
Several nuclear receptors (NRs), including peroxisome prolifera-
tor-activated receptors (PPARs), thyroid hormone receptors (TRs) and
estrogen-related receptors (ERRs), have emerged as important
metabolic regulators [13]. These receptors control the transcription
of genes involved in metabolic pathways underpinning the
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regulate gene transcription depends on the recruitment of coactiva-
tors and corepressors that remodel chromatin in the vicinity of the
promoters. Both the expression and activity of cofactors are subject to
regulation by a number of signalling pathways in a tissue-speciﬁc
manner. The activity of many receptors is suppressed in the absence of
ligand passively, in complexes with heat shock proteins in the
cytoplasm, as in the case of androgen receptor (AR) and glucocorti-
coid receptor (GR) [14,15]. Some NRs, including TR, retinoid X
receptor (RXR) and PPARs, can be actively repressed by recruitment of
corepressors, such as nuclear receptor corepressor (NCoR) and
silencing mediator of retinoic acid and thyroid hormone receptor
(SMRT) [16,17]. Ligand binding results in conformational changes
which lead to the dissociation of repressive complexes and the
recruitment of coactivators, such as p300/CBP, p160/steroid receptor
coactivator (SRC) and PPARγ coactivator (PGC) families, to activate
transcription [18,19]. Ligand binding may not only result in the
activation of subsets of genes but also the repression of certain genes.
Receptor interacting protein (RIP) 140 was found to function as a
corepressor for a number of ligand bound nuclear receptors with a
role in metabolism (TR2, PPARs, LXRα, GR, retinoic acid receptor
(RAR)/RXR) [20–25]. RIP140 is itself highly expressed in metabolic
tissue like adipose tissue, skeletal muscle and liver [26]. Genome-wide
expression arrays studies have highlighted its role as a global regulator
of energy balance, repressing multiple metabolic pathways to reduce
energy expenditure. On the other hand, recent studies have shown that
RIP140 also functions as a coactivator for NR [22,27] or other types of
transcription factors [28,29]. The molecular basis for these opposing
functions is poorly understood and this review will focus on the
biological roles of RIP140 in metabolism and inﬂammation and
considers how targeting its function may provide an approach to
treatment of metabolic syndrome.AS160
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Fig. 1. Actions of RIP140 in adipocytes. Nuclear RIP140 is recruited by nuclear receptors
to repress sets of genes that promote energy consumption. Glut4 gene is also
transrepressed and the action of Glut4 protein is inhibited by cytoplasmic RIP140,
contributing to insulin resistance. Cytoplasmic translocation of RIP140 is stimulated by
PKCε-mediated phosphorylation, followed by 14-3-3-dependent recruitment of
PRMT1, arginine methylation and export through exportin1. This sequence of post-
translational modiﬁcations is promoted under a high-fat diet. PKCε, protein kinase Cε;
PRTM1, protein arginine methyl transferase 1; HFD, high-fat diet.2. Role of RIP140 in adipose tissue
Both white (WAT) and brown (BAT) adipose tissue share many
common features such as their ability to take up glucose, synthesize
and store triacylglycerides (TAG), and mobilize those TAG in
situations of energy demand. However, they play largely opposing
roles in mammalian physiology.WAT serves as the prime reservoir for
storing excess caloric energy in the form of TAG. It is also an important
source of endocrine hormones involved in metabolic regulation such
as leptin, adiponectin, and resistin [7,30]. In contrast, BAT is the major
site of adaptive thermogenesis capable of generating heat from fatty
acid oxidation to maintain body temperature, particularly in response
to cold exposure [31]. Thus, it is a net consumer of caloric energy. BAT
is also a site of diet-induced thermogenesis [31]. The function of
brown adipocytes is critically dependent on the expression and
activity of uncoupling protein (UCP) 1, a mitochondrial protein almost
exclusively found in BAT and therefore considered as a key molecular
marker [31]. That WAT and BAT play an important role in the
maintenance of energy homeostasis is reﬂected in the observation
that small alterations in their function can have a large impact on
whole-body metabolism [31]. Moreover, the ability of white and
brown adipocytes in each depot to reversibly switch into one another
has been reported [30,32,33], but the extent to which this occurs and
the precise mechanisms involved are not fully understood (reviewed
in [34]). The search for regulators that could mediate conversion of
white adipocytes (energy storing) into brown adipocytes (energy
consuming) has led to the identiﬁcation of PGC1α, forkhead-box
(FOX) C2 and positive regulatory domain-containing (PRDM) 16 as
transcriptional regulators that have been found to promote a brown
fat genetic program, while retinoblastoma protein and RIP140 have
been described to favour awhite adipose phenotype (reviewed in refs.
[35,36]).RIP140 is most highly expressed in WAT where it regulates the
expression of many genes involved in catabolic pathways (energy
consuming), especially those involved in lipid and glucose metabo-
lism. Mice devoid of the coregulator express higher levels of genes
that regulate fatty acid oxidation and proteins involved in energy
dissipation, highlighting its role as a corepressor and its role
controlling the balance between energy consumption and energy
expenditure [26]. On the contrary, genes involved in FA synthesis and
gluconeogenesis seem to be downregulated in the absence of RIP140.
As a consequence, RIP140 null mice are lean, with a 70% reduction of
body fat and a 20% reduction in body weight compared to wild-type
mice and they are resistant to high-fat diet (HFD) induced obesity and
hepatic steatosis so that the mice maintain their insulin sensitivity
[26,37]. It is particularly noteworthy that in the RIP140 KO animals
WAT expresses genes characteristic of BAT including UCP1, fatty acid
transporter carnitine palmitoyltransferase (CPT-1β) and the lipid
droplet protein cell death-inducing DNA fragmentation factor alpha-
like effector A (CIDEA). Targeted disruption in mice of several genes
directly involved in energy metabolism and fat accumulation (LXRα,
ERRα and retinoblastoma protein) also leads to a lean phenotypewith
a marked increase in UCP1 expression in adipocytes, particularly in
white fat depots (see ref. [38] for a review). RIP140 expression is very
low in preadipocytes and induced upon differentiation [37,39,40].
Studies in different adipocyte cell models (3T3-L1, MEFs (mouse
embryonic ﬁbroblasts), immortalised white adipocytes) have shown
that RIP140 is not required for adipocyte differentiation. Analysis of
gene expression proﬁles from the RIP140 null cell lines show that,
RIP140 modulates the expression of similar genes involved in fatty
acid and carbohydrate metabolism found in WAT, indicating that it
functions as a cell autonomous corepressor. Most of the upregulated
genes in the RIP140-null adipocytes are genes involved in catabolic
pathways including fatty acid oxidation, oxidative phosphorylation,
glycolysis and the tricarboxilic acid cycle (Fig. 1). Again, some genes
normally restricted to expression in BAT, including UCP1, CIDEA and
CPT1-β, are elevated in RIP140-null adipocytes [37,39]. Many of the
genes regulated by RIP140 are also targets for the coactivator PGC1α
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response to cold. PGC1α is a key regulator of mitochondrial biogenesis
and oxidative metabolism in tissues with high oxidative capacity such
as skeletal muscle, liver and brown fat by acting as a coactivator for a
number of different transcription factors involved in metabolic
control [41]. Since RIP140 also can bind to and repress many of
these transcription factors, including PPARα, PPARγ and ERRα [21,39]
it appears that the PGC1α and RIP140 coregulators may play mutually
opposing roles in controlling sets of metabolic genes. We have found
that both coregulators can be recruited simultaneously to the CIDEA
promoter and it's noteworthy that they are able to physically interact.
These observations suggest that RIP140 may be acting as a
transcriptional brake that could be overcomed under conditions
when the expression or activity of the coactivator is increased [42].
Recent studies by Li Na Wei and her colleagues indicate that
RIP140 may not only be a transcriptional coregulator but may also
function in the cell cytoplasm. They have found that cytoplasmic
RIP140 inhibits glucose metabolism by reducing insulin-stimulated
glucose transporter 4 (GLUT4) trafﬁcking and glucose uptake [43]
(Fig. 1). Importantly, the same study shows that high-fat feeding
results in cytoplasmic localization of RIP140 in epididymal white
adipocytes, highlighting the biological relevance of a function for
RIP140 in the cytoplasm. The cytoplasmic role of RIP140 is in addition
to the direct regulation of GLUT4 mRNA expression by RIP140 in
mouse and human adipocytes [37,40]). These ﬁndings provide the
basis for a novel mechanism by which RIP140 might impair glucose
utilization and promote insulin resistance. The observations also
suggest that irrespective of RIP140 expression levels it may also be
important to establish whether there are changes in compartmental-
ization of the protein.
Very few studies have been carried out in humans. A decrease in
RIP140 mRNA in biopsies of visceral WAT depots from obese patients
has been reported with a strong correlation between bodymass index
and RIP140mRNA levels [44]. It is conceivable that decreased levels of
RIP140 serve as a compensatory mechanism to favour energy
expenditure to reduce fat accumulation. In another study no
difference was found in RIP140 expression between obese and lean
women with polycystic ovary syndrome (PCOS), or between obese
PCOS and lean controls [45]. Finally, a recent study shows that RIP140
is decreased in subcutaneous adipose tissue of obese women and
increased by weight loss. In the same study, in primary culture of
human adipocytes, RIP140 expression increased during adipocyte
differentiation and its knockdown increased basal glucose transport
andmRNA levels of GLUT4 and UCP1, a similar behaviour to that of the
mouse ortholog [46]. Overall, high levels of human RIP140 in WAT of
lean subjects may minimise energy utilization from depleted fat
stores. At ﬁrst sight, the overexpression of RIP140 in tissues from
obese individuals would be predicted from the mouse studies, where
its absence promotes reduced TAG accumulation; but on the other
hand, the subcellular localisation of RIP140was not examined in these
studies and we have yet to elucidate signalling pathways that may
control of the activity of RIP140 by post-translational modiﬁcations.
RIP140 is highly expressed in BAT albeit to a lesser extent than in
WAT. Interest in the study of BAT physiology has been renewed by
recent demonstration of considerable amounts of active tissue in
many adult humans [47–50]. In adult knock-out mice, the size and
appearance of BAT is similar to the wild-type animals [26]. At the
molecular level, UCP1 expression, together with the expression of
nuclear receptors PPARα, PPARγ, and fatty acid transporter aP2 is
similar in both knock-out and wild-type animals. These ﬁndings
suggested that BAT might not be a major site for RIP140 function or at
least its lack of expression would not seem to have a big impact under
basal conditions. Nevertheless, some recent experiments seem to
point out a role for RIP140 in BAT. It has been shown that adult
RIP140-null mice exhibit a reduced body core temperature and
reduced mRNA expression of coregulator PGC1α in BAT, althoughresponse to an adrenergic activator does not seem impaired in these
animals [51]. This is consistent with in vitro observations [21].
However, newborn and young RIP140-null mice exhibit a signiﬁcant
reduction in BAT mass and PGC1αmRNA expression, which might be
associated with poor thermogenesis and that this in turn might
account for the poor rate of postnatal survival [51]. More recently, in a
cell line model of brown adipocytes, RIP140 was found to be recruited
to and repress the CIDEA promoter through binding to both ERRα and
nuclear respiratory factor (NRF) 1 [42]. Moreover, RIP140 has also
been described to target and repress UCP1 enhancer in brown
adipocytes trough LXR binding [23]. These ﬁndings suggest a role
for RIP140 in BAT physiology, which might not be as evident as in
WAT, but which could have important implication regarding energy
expenditure. Further studies need to be carried out in both adults and
newborn mice in order to establish the exact role of RIP140 in this
tissue.
The amount of BAT and the expression of UCP1 correlate with
increased basal metabolic rate and protection from obesity in both
mice and humans. Genetic ablation of BAT induces obesity in mice
[52]. Likewise, genetic deletion of UCP1 in mice causes weight gain
when mice are kept at thermoneutrality [53]. On the other hand,
ectopic expression of UCP1 in WAT results in resistance to obesity
[54]. Mice with an increase in the amount of active BAT gain less
weight and are more insulin-sensitive. Indeed, BAT mass and activity
is greatly decreased in obese patients, particularly those with morbid
obesity [50,55]. Therefore, the increased expression of genes in WAT
from RIP140 null mice that are usually restricted to BAT seems to
compromise the function of this tissue as the site of energy storage.
Total energy consumption is increased signiﬁcantly in RIP140-null
mice, presumably as a consequence of energy dissipation in WAT
resulting from the expression of UCP1 and increased mitochondrial
activity [26]. BAT, on the other hand, utilises energy not only lipid
oxidation but also glucose metabolism. Given the high metabolic
capacity of BAT, any reduction in the amount or activity of BAT could
perturb the ability of the body to dispose of glucose. Accordingly, the
maintenance of a high glucose-utilizing activity by BAT could prevent
the development of glucose intolerance and insulin resistance. As
RIP140 has been found to control glucose metabolism in white
adipocytes it will be of high interest to study its role in glucose
metabolism in BAT. Glucosemetabolism in BAT is under insulin and β-
adrenergic control. β-Adrenergic responses were found to be
unaltered, at least in primary cultures of brown adipocytes from
RIP140 null mice [21]. It will be interesting to determine whether
insulin signalling is affected when RIP140 levels are modiﬁed and
whether high levels of RIP140 inhibit oxidative metabolism and
expression of genes involved in thermogenesis, which could have a
vast impact on the total energy expenditure in an individual.
3. Role of RIP140 in inﬂammation
Lipotoxicity and inﬂammation are intimately involved in the
evolution of a number of metabolic diseases. Lipid overload of
macrophages in vascular endothelium leads to phenotypic transfor-
mation into foam cells, secretion of pro-inﬂammatory cytokines, and
apoptosis, contributing to atherosclerosis [56]. In steatotic liver,
activation of kupffer cells, the residentmacrophages, can drive hepatic
inﬂammation and transition to steatohepatitis [57]. Accumulation of
lipoproteins and lipid derivatives in the kidney induces macrophage
inﬁltration and activation to initiate renal inﬂammation in chronic
kidney disease [58]. Obesity in mice and humans is associated with a
low-grade subclinical inﬂammation of adipose tissue [59–62]. Non-
obese adipose tissue contains a quiescent population of local
macrophages with little pro-inﬂammatory activity to support adipo-
cyte function and maintain insulin sensitivity [63]. When hypertro-
phic, adipocytes secrete higher amounts of chemo-attractants to
promote macrophage inﬁltration [9]. Additional macrophages may
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are more abundant in obese adipose tissue [30,64]. Free FA spill-over
from enlarged adipocytes is able to activate Toll-like receptor (TLR)
signalling and downstream Janus N-terminal kinase (JNK) and nuclear
factor κB (NF-κB) pathways in the resident macrophages to elicit a
switch towards a classically activated, pro-inﬂammatory phenotype
[65,66]. The subsequent production of pro-inﬂammatory cytokines,
including IL6 and TNFα, will interfere with insulin signalling leading
to type 2 diabetes and further propagate the state of chronic
inﬂammation [67,68]. The importance of inﬂammation in metabolic
diseases has been reinforced by studies showing that limiting
macrophage activation [67,69–71] and production of pro-inﬂamma-
tory signals [72] is of value in reducing insulin resistance.
In contrast to the corepressor activities in adipose tissue and
muscle, RIP140 can function as a coactivator in macrophages (Fig. 2).
Comparison of gene expression proﬁles of macrophages derived from
wild-type and RIP140 null mice has revealed that RIP140 deﬁciency
impairs full execution of the pro-inﬂammatory program in response
to TLR-mediated activation [29]. Downstream of TLRs, NF-kB is a
major transcriptional regulator of pro-inﬂammatory gene expression,
including TNFα, IL1β and IL6. RIP140 is recruited to these NF-κB-
dependent promoters and stimulates transcription by acting as aFig. 2. In muscle cells RIP140 functions as a corepressor for nuclear receptors to repress gen
dependent pro-inﬂammatory genes. In hepatocytes RIP140 is both a corepressor and coa
gluconeogenesis.bridging factor, stabilizing the formation of a trimeric complex with
the RelA subunit and the CBP coactivator [29]. It is noteworthy that
the absence of RIP140 causes only a partial attenuation of pro-
inﬂammatory gene transcription and in cells where RelA expression is
not limiting the coregulatory contribution of RIP140 might be modest
[29]. Thus, the levels of transcription factors and other interacting
cofactors can dictate the efﬁciency of a particular coregulator. This is
an important concept when considering the inﬂammatory phenotype.
RIP140 absence does not appear to immunocompromise mice [73,74]
since pathogens provoke a strong immune reaction and in this context
the function of RIP140 may have only a minor impact. However, in a
more subtle state of inﬂammation, as found in obese adipose tissue,
the absence of even a relatively weak activator might have a more
pronounced outcome. Although insulin sensitivity in RIP140 null mice
fed a high-fat diet is better than that in wild-type mice [37], the
relative contribution of a blunted inﬂammatory response in macro-
phages relative to the altered lipid metabolism in adipose tissue, liver
and muscle is unclear [22,26,75]. More insights would be provided by
generation of mice with myeloid speciﬁc RIP140 deletion.
It is perhaps surprising that the expression of metabolic genes is
essentially unaltered in macrophages in the absence of RIP140 in
contrast to the situation in skeletal muscle and adipocytes [29]. Thesees involved in oxidative metabolism. In macrophages RIP140 is a coactivator for NF-κB-
ctivator for LXRα-dependent gene transcription to promote lipogenesis and reduce
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[22], which play important roles in the control of lipid homeostasis
and inﬂammation in response to endogenous fatty acid or sterol
ligands. These NRs have been documented to mediate repressive
effects on inﬂammatory genes in an NCoR- and SMRT-dependent
manner [76–78]. It remains to be investigated if in macrophages,
PPARs and LXRs can also form repression complexes with RIP140 on
some genes, which would provide an interesting setting, where the
coregulator has negative as well as positive functions.
Communications between adipocytes and macrophages are im-
portant in triggering inﬂammation in adipose tissue and it is
increasingly recognized that both cell types contribute to the
development of obesity-induced insulin resistance. Although the
inﬁltrated macrophages are the main source of TNFα, adipocytes are
responsible for a sizable fraction of the IL6 concentration in the
circulation of obese patients [79,80]. The importance of an inﬂamma-
tory response within adipocytes themselves is clear from a study with
mice with adipocyte-speciﬁc JNK1 deﬁciency, which have improved
insulin sensitivity in response to high-fat diet and normal levels of
serum IL6 [67]. Interestingly, microarray interrogation of gene
expression proﬁles shows that depletion of RIP140 in adipocytes
causes genes encoding proteins involved in catabolic pathways for
carbohydrates and fatty acids to be upregulated, but a subset of pro-
inﬂammatory genes, including IL6, are downregulated (D. Morgen-
stein, unpublished observations;[39]). Therefore the activity of RIP140
as a coactivator of pro-inﬂammatory gene expression is unlikely to be
restricted to macrophages and may also be found in adipocytes and
possibly other cell types. Thismerits further investigation, for example,
in vascular endothelial cells, where inﬂammation is the basis for
atherosclerosis, or in the muscle, where macrophage inﬁltration and
activation can give rise to muscle insulin resistance [81,82], andwhere
copious amounts of IL6 are produced during exercise [83].
4. Role of RIP140 in muscle
4.1. Skeletal muscle
In both mouse and human, skeletal muscle contains distinct types
of ﬁbres, characterized by differential expression of speciﬁc myosin
heavy chains. This difference in ﬁbre composition accounts for
different types of contractile function. Type I ﬁbres (slow twitch
ﬁbres) are rich in mitochondria and show high levels of oxidative
phosphorylation relaying mainly on fatty acid oxidation. These are the
ﬁbers resistant to fatigue and predominant in red muscles, such as the
soleous. Type II (fast twitch ﬁbers) contain a low number of
mitochondria and relay more on anaerobic respiration via glycolysis
or glycogenolysis that enable them to undergo rapid and short
contractile bursts. In comparison to type I ﬁbers, type II are more
prone to fatigue. These types of ﬁbers are predominant in muscles like
the gastrocnemius and extensor digitorum longus (EDL) [84]. There is
also an intermediate type of ﬁbers, type IIX, that have fast twitch
characteristics, but depend on oxidative metabolism that is similar to
type I ﬁbres [85]. Muscle ﬁber type composition can be modulated in
response to several factors such as exercise, aging, hormonal changes
or disease [86,87]. An increase in exercise has been shown to induce a
ﬁbre composition switch in the amount of type I ﬁbres inmuscles with
predominantly Type II ﬁbers such as the gastrocnemius. The switch in
ﬁber type is reﬂected by changes in the expression of the myosin
isoforms and other ﬁber type markers, as well as an increased
expression of genes involved in mitochondrial myogenesis, fatty acid
oxidation and oxidative phosphorylation. At a molecular level, a
number of transcriptional regulators that are able to remodel skeletal
muscle have been identiﬁed but it is still uncertain how the pathways
are regulated. Nuclear receptors including PPARs, ERRα and other
transcription factors such as CRE-binding protein (CREB), myocyte-
speciﬁc enhancer binding factors (MEFs), activating transcriptionfactors (ATFs) and NRFs have been found to activate expression of
metabolic genes in skeletalmusclewhile the PGC1αplays a pivotal role
as a coactivator for the aforementioned transcription factors [88,89].
Skeletal muscles play an important role inwhole-bodymetabolism
as they account for the 70% of the total insulin-stimulated glucose
uptake. Alterations in its function or ﬁbre composition can have a big
impact on the whole-body metabolism. For example, in insulin-
resistant states, such as obesity and type II diabetes, insulin-
stimulated glucose uptake is markedly impaired [90], while increasing
the number of type I ﬁbres enhances insulin-mediated glucose uptake
and protects against diabetes and other metabolic diseases [91].
Moreover, in obese patients, skeletal muscles have reduced metabolic
oxidative capacities with morphologic changes that reveal decreased
type I slow twitch ﬁbers [92].
In skeletal muscle, RIP140 is expressed in a ﬁber type speciﬁc
manner. RIP140 mRNA levels seem to be higher in glycolytic muscles,
like gastrocnemius and EDL, rather than in oxidative muscles, like
soleus and diaphragm [75]. In the absence of RIP140, EDL and
gastrocnemius muscles exhibit a marked increase in mitochondrial
activity accompanied by a corresponding shift in myoﬁbers favouring
the more oxidative type. Muscles appear redder in colour and express
increased levels of type I ﬁbres markers. These changes are
accompanied by an increase in mitochondrial number and oxidative
metabolism (most notably fatty acid oxidation) and are coordinated
following upregulation of genes involved in these processes [75].
PPARδ and ERRα are direct targets for RIP140 action at least for some
of the genes. Conversely, in transgenic animals, elevated RIP140
expression resulted in a decrease in both mitochondrial activity and
the number of oxidative myoﬁbers [75]. In contrast, muscles that
consist of predominantly type I ﬁbres (usually expressing low RIP140
levels) show an unaltered phenotype in the RIP140 null mice. This is
consistent with the function of RIP140 as a corepressor and suggests a
role for RIP140 as an inhibitor of oxidative metabolism in skeletal
muscle [75] (Fig. 2). Considering the mass of skeletal muscle it can
have an important impact on thewhole-body energetic metabolism. It
is conceivable that alterations in RIP140 expression may contribute to
certain metabolic diseases such as obesity, insulin resistance and type
II diabetes but this will require further investigation.
4.2. Cardiac muscle
Recent evidence suggests that impaired myocardial mitochondrial
biogenesis, fatty acid metabolism, and antioxidant defence mecha-
nisms lead to diminished cardiac substrate ﬂexibility, decreased
cardiac energetic efﬁciency, and diastolic dysfunction. These mito-
chondrial abnormalities can predispose to a metabolic cardiomyop-
athy and have been observed in insulin-resistant animal models and
persons that are at higher risk of developing type 2 diabetes mellitus,
hypertension, and cardiovascular disease [93].
RIP140 mRNA expression is high in cardiac muscle [26,94]. Studies
in transgenic mice overexpressing RIP140 show that these mice are
characterized by rapid onset of cardiac hypertrophy and ventricular
ﬁbrosis which results in an increase in themortality rate from 4weeks
of age [26,94]. Interestingly, females are less sensitive to the
deleterious effects of exogenous RIP140 expression compared to
males, suggesting that estrogens might play a protective role against
cardiac hypertrophy [95]. In these mice, overexpression of RIP140
leads to reduced expression of genes involved in fatty acid transport/
oxidation and mitochondrial activity. This is accompanied by a
decrease in mitochondrial number and activity, as demonstrated by
decreased state III and state IV membrane potential and oxygen
consumption, associated with abnormal morphology [94]. Thus,
decreased energy production associated to increased ﬁbrosis might
be responsible for impaired cardiac function and decreased survival
observed in the RIP140 transgenic mice. This study is consistent with
data for skeletal muscle and myotubes obtained from RIP140-null
Rip140
ADIPOCYTE MYOCYTE
HEPATOCYTEMACROPHAGE
pro-energy storage
insulin resistance
pro-type II 
glycolytic fibre type
pro-inflammatory pro-lipogenic
anti-gluconeogenic
Fig. 3. Actions of RIP140 in different metabolic tissue.
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olism [75]. Moreover, it highlights the importance of RIP140 in
postnatal cardiac function and the possible implication in adult
mitochondrial dysfunction leading to myopathies and cardiac
malfunction.
5. Role of RIP140 in the liver
The hepatic manifestation of the Metabolic Syndrome is non-
alcoholic fatty liver disease (NAFLD) and it is associated with
insulin resistance although the cause and consequence relationship
is debated [96,97]. NAFLD is diagnosed as the histological presence
of lipid in more than 5% of hepatocytes, which is mostly in the
form of TAG derived from the circulating pool of non-esteriﬁed
fatty acids (59%), diet (15%) or de novo synthesis (26%) [98].
Hepatic lipogenesis is regulated by LXRα [99,100] and two studies
have identiﬁed roles for RIP140 in this process. Our lab has found
that in response to high-fat diet or agonist treatment, RIP140 is
able to act as a coactivator for LXR-dependent induction of sterol
regulatory element binding protein (SREBP) 1c and fatty acid
synthase (FAS), which promote TAG synthesis [22]. Interestingly,
RIP140 is also required for LXR-dependent repression of phospho-
enolpyruvate carboxykinase (PEPCK) gene to limit gluconeogenesis
in hepatocytes. Therefore, RIP140 and LXR can partner to form
distinct activator or repressor complexes to either promote lipid
generation or reduce glucose production, respectively [22] (Fig. 2).
In contrast, a second study has shown that RIP140 contributed to
hepatic steatosis during starvation and cancer cachexia by
repressing SREBP1c [73]. In addition, RIP140 knockdown in the
liver of starved mice altered hepatic FA oxidation, very low density
lipoprotein (VLDL) production, FA uptake, serum TAG and
peripheral LPL activity, to have a wider effect on local and
systemic lipid homeostasis [73]. The reason for the contradicting
results is not clear but differences in the experimental models
used may have a contribution. We have utilized high-fat diet-
induced liver steatosis with whole-animal RIP140 knockouts, as
opposed to starvation or cachexia-triggered steatosis accompanied
by shRNA-mediated liver-speciﬁc RIP140 knockdown. Nevertheless,
both studies have found that RIP140 absence is beneﬁcial by
lowering hepatic TAG content in the given experimental context.
Further experiments, perhaps making use of hepatocyte-speciﬁc
RIP140-null animals, are required to understand the precise
functions of the cofactor in this tissue.
6. Targeting RIP140 for treatment of metabolic syndrome
Lipotoxic events are the underlying cause of cellular damage in the
metabolic syndrome and therefore tackling the oversupply of lipid to
affected organs is important. Reducing caloric intake and increasing
exercise to favour a negative energy balance should lead to clearance
of ectopic lipid deposition and improve an array of metabolic
parameters [101,102]. Nevertheless, although lifestyle changes are
beneﬁcial, obesity remains difﬁcult to combat. A pharmacological
approach is to increase the lipid storage capacity of subcutaneous
adipose depots with a view to prevent overspill and accumulation in
non-adipose organs. This is exploited by the thiazolidinedione (TDZ)
class of drugs, which, by activating PPARγ, promote preadipocyte
differentiation in addition to its insulin sensitizing effects [103]. Thus,
the improved whole-body insulin sensitivity and reduced hepatic and
visceral lipid content is attributed at least in part to the hyperplasic
increase in subcutaneous adipose tissue seen in patients or animal
models treated with TDZ [104–106]. In this case however, an
improvement in metabolic well-being comes with increased obesity
as a side-effect.
Excess fatty acids reaching non-adipose tissue can be activated to
fatty acyl-CoA (FACoA) that undergo a series of esteriﬁcation reactionto form lysophosphatidic acid (LPA), phosphatidic acid (PA),
diacylglycerol (DAG) and ﬁnally TAG. Alternatively, FACoA can be
channelled down the sphingosine synthesis pathway, where cera-
mide is an intermediate, or it can undergo β-oxidation to feed the
mitochondrial electron transport chain [107]. All three fates have the
potential to present the cell with toxic challenges. LPA, PA, DAG and
ceramide can activate pro-inﬂammatory kinases to contribute to
insulin resistance [108–111]. Indeed, ceramide levels are elevated in
skeletalmuscle of obese humans [112,113] and can further antagonize
insulin signalling by inhibition of Akt [114]. Increasing the ability to
oxidize FA, especially in the mitochondria of skeletal muscle, would
reduce the accumulation of such intermediates and therefore protect
from insulin resistance. It is important to note that several lines of
evidence have questioned the role ofmitochondrial function in insulin
sensitivity and the cause and consequence relationship between the
two remains highly debated [115]. Nevertheless, mitochondrial
overload with lipid supply would increase reactive oxygen species
(ROS) production, which has been shown to have a causal role in
insulin resistance [116]. An important facet of treatment of metabolic
disorders is limiting the damaging effects of the three possible fates of
fatty acids, and RIP140 is involved in regulation of all three.
The pathways underlying the metabolic syndrome are interlinked
in a complex network and an effective approach to treatment may
need to target multiple points. For example, TDZ treatment, which
activates PPARγ to reduce inﬂammation and promote adipogenesis
and enhances adiponectin secretion to increase lipid oxidation
[117,118], is often prescribed in conjunction with metformin to
reduce gluconeogenesis in the liver, improve glucose uptake in
peripheral tissue and overall insulin sensitivity. The evidence
accumulated form studying RIP140 suggests that targeting the
function of this cofactor for treatment of metabolic disorders would
be of particular value since it would also have multiple beneﬁcial
consequences (Fig. 3). As detailed above, RIP140 null mice have a
hypermetabolic phenotype, largely as a result of upregulation of genes
involved in FA β-oxidation, oxidative phosphorylation, TCA cycle and
mitochondrial biogenesis in adipose tissue and muscle [37,75]. This
causes WAT to function in a manner akin to BAT to expend stored fat
for thermogenesis, while in skeletal muscle the proportion of type I
oxidative ﬁbres, where TAGs are mainly used as fuel, is increased.
Consequently, lipids are removed from the circulation, and both
visceral and subcutaneous fat depots are reduced [26]. The upregula-
tion of UCP1 inWAT [119] may also limit the amount of ROS produced
by the mitochondria [120] to prevent inhibition of insulin signalling.
Absence of RIP140 may have an additional protective effect on insulin
signalling by preventing downregulation and inhibition of GLUT4
[43]. Impairing RIP140 function would protect against hepatic
steatosis during a lipid challenge by promoting gluconeogenesis and
reducing lipogenesis. Here, downregulation of SREBP1c and FAS
restricts de novo FA synthesis [22], therefore reducing both TAG and
sphingolipid biosynthetic pathways and the production of harmful
intermediates. Furthermore, absence of RIP140 in macrophages
would decrease the inﬂammation associated with obesity and insulin
resistance [29]. The net results are improved lipid partitioning
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size to allow it to regain normal lipid homeostatic function, and
consequently, improved insulin sensitivity. The phenotype of RIP140
null mice is proof of principle that targeting RIP140might constitute a
successful approach for the treatment of metabolic syndrome.
Although caution must be exercised since RIP140 function is essential
for female fertility [28,121,122], this might not necessarily be a
priority since metabolic disorders prevail at an age past sexual
reproduction. Drugs seldom approach 100% efﬁciency, however, even
a 50% inhibition of RIP140 activity would be beneﬁcial, since
heterozygous mice challenged with a high-fat diet also display
improved metabolic parameters at a level intermediate between
wild-type and null animals [74,75].
What pharmacological approaches could be used to modulate the
function of RIP140? Three possibilities are outlined: (a) regulation of
RIP140 expression, (b) regulation of RIP140 activity and (c) regulation
of NR-dependent recruitment. In the ﬁrst instance, several NR ligands
have been shown to control RIP140 expression. In breast cancer cells
estrogens [123], retinoic acid [124] and androgens [125] upregulate
RIP140 mRNA levels thus providing potential feedback loops to limit
nuclear receptor action. Estrogen antagonists may therefore be of
value in preventing an induction in RIP140 expression [125], while
progestins have been found to modestly downregulate RIP140 mRNA
[126]. However, the use of such compounds would not offer efﬁcient
action in metabolic tissues that are largely non-responsive to steroid
sex hormones. More interestingly, ERRs, which have been implicated
in control of energy metabolism, can activate RIP140 gene expression
by directly binding to an ERRE and indirectly through SP1 binding
sites in the promoter [127]. ERRα-null mice have reduced body
weight and peripheral fat deposits [128], reminiscent of the RIP140-
null phenotype, yet the lack of a known ligand leavesmodulation of its
activity a difﬁcult proposition. Recently miRNA have become very
attractive tools in manipulating gene expression. The 5′ UTR of the
RIP140 mRNA has been found to be targeted by microRNA (miRNA)
mir-346. Rather than silencing RIP140 expression, mir-346 has been
found to function in an atypical manner, increasing the protein levels
and therefore the repressive activity of the cofactor, but a miRNA
antagomir can be used to dampen RIP140 activity [129]. Furthermore,
RIP140 mRNA contains a large 3′ UTR of ~3.5 kb that remains to be
investigated for target sites of additional miRNAs.
In its role as a transcriptional regulator, RIP140 lacks any intrinsic
enzymatic activities but is thought to function as a scaffold protein,
providing a platform for the recruitment of enzymes such as C-
terminal binding protein (CtBP) [130], histone deacetylases (HDACs)
[131], DNAmethyltransferese (Dnmt) [119], CBP [29], that change the
accessibility of the promoter to the transcription machinery. Post-
translational modiﬁcations (PTMs) lie at the basis of regulating the
activity of non-enzymatic proteins. By favouring or disrupting speciﬁc
interactions, PTMs can alter not only the recruitment of transcrip-
tional complex partners but may also have wide-ranging conse-
quences on the behaviour of proteins, including changes in subcellular
localization and half-life. RIP140 is subject to a diverse array of PTMs.
Multiple site of phosphorylation [132], acetylation [133], arginine
[134] and lysine methylation [135] have been identiﬁed in RIP140 by
mass spectrometry-based studies. Vitamin B6 [136] and SUMO
conjugation [137] have also been described and may also modulate
RIP140 function. Several PTMsmay engage in an interplay tomodulate
RIP140 activity and affect cellular function. For example, PKCε-
stimulated phosphorylation promotes PRTM1-directed arginine
methylation to reduce RIP140 gene repressive activity by preventing
interaction with HDAC3 and facilitating its export to the cytoplasm
[134,138]. Conversely, MAPK-mediated RIP140 phosphorylation may
enhance repressive activity [139,140]. Post-translational modiﬁca-
tions are often investigated by ablating or mimicking them with the
use of point mutations of modiﬁcation sites. A caveat to such
experiments is that a single amino acid can be subject to severalmodiﬁcations. For example, interpretation of results of a lysinemutant
is complicated by the potential of the amino acid to undergo
acetylation, methylation, SUMOylation or ubiquitination. However, if
well validated, mechanistic knowledge of PTMs in RIP140 might be
exploited for therapeutic purposes by targeting upstream signalling
pathways that control its activity.
A third method of regulating RIP140 function involves taking
advantage of its recruitment by NR. Partial agonists or antagonists
may selectively prevent interaction with RIP140 while not interfering
with other activities of the receptor. Since the metabolic repressor
action of RIP140 is supported by NR-dependent recruitment, the
discovery of such compounds would prove valuable for limiting the
dampening effect on catabolism in adipose tissue and skeletal muscle.
Notably, MRL24 has been recently identiﬁed as a PPARγ minimal
agonist that inhibits Cdk5-mediated receptor phosphorylation to
prevent obesity-associated gene dysregulation in fat cells [141]. Since
chromatin occupancy of PPARγ was not altered, it is likely that
differential recruitment of coregulators is responsible for the observed
effect. Such a ﬁnding should encourage screening of ligands for PPARγ
and other nuclear receptors for selective interaction with RIP140.
7. Conclusions
Overall this article summarizes the regulatory effects of RIP140 in
tissues with an important role in the development and progression of
the metabolic syndrome including white and brown adipose tissue,
inﬂammatory cells, skeletal and cardiac muscles and liver. We have
outlined signalling pathways that are subject to regulation by RIP140
and contribute to the development of the metabolic syndrome and
speculated about the possibility of targeting RIP140 to ameliorate
associated metabolic disorders.
In our opinion, therapeutic strategies targeting RIP140 have to be
considered with caution, considering the broad spectrum of actions of
RIP140 as well as its recently described role as a coactivator. Given that
RIP140 is likely to be a difﬁcult metabolic target to ﬁnely tune it would
be necessary to screen for compounds that modify the recruitment of
RIP140 to speciﬁc nuclear receptors at a subset of genes, or
alternatively, compounds that canalter its binding toother components
of the transcriptional machinery, such as histone modifying enzymes.
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